Regeneron Will Seek Approval For Eylea In DME This Year
This article was originally published in The Pink Sheet Daily
Encouraging Phase III trial results will prompt the specialty pharma to submit its strong-selling ophthalmological entrant for another approval in diabetic macular edema. Regeneron already expects domestic sales of the drug to exceed $1 billion this year.
You may also be interested in...
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.
FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.